Investor Presentation First Nine Months of 2022
51
Investor presentation
First nine months of 2022
Insulin icodec, a basal insulin intended for once-weekly
treatment, may reduce the disease burden for patients
Bringing the strongest value
proposition to market
Insulin icodec phase 3 programme completed in 2022
Reduction of disease burden with
ONWARDS 1
984 people insulin-naïve, 78-week, vs insulin glargine U100
once-weekly treatment
ONWARDS 2
Tested for superior HbA1c and TiR vs
glargine and standard-of-care and
526 people on basal, 26-
week, vs insulin degludec
588 people insulin-naïve, 26-week,
ONWARDS 3
similar safety profile of Tresiba®
vs insulin degludec
App-based offering and connected
ONWARDS 4
smart pen to optimise titration and
support compliance and data
collection
ONWARDS 5
ONWARDS 6
Reduced
environmental footprint
582 people on both basal and bolus, 26-week,
vs insulin degludec
1,085 people, insulin-naïve using app-based dosing
recommendations, 52-week
582 people, type 1 diabetes using bolus insulin, 52-week,
vs insulin degludec
TIR: Time-in-range
Note: For ONWARDS 1 and ONWARDS 6 main phases are completed
2022
Novo NordiskⓇView entire presentation